Tilray Brands, Inc.

by admin

Tilray Brands, Inc. is a global pharmaceutical, consumer packaged goods, and cannabis lifestyle company. Its headquarters are in New York City and its operations are based in Canada, Australia, New Zealand, and Germany. It has growing facilities in Portugal and Germany. Its products are available in the United States, Canada, and other countries.

Tilray stock began trading on Nasdaq in July 2018. It was the first pure-play cannabis company to IPO on the Nasdaq. The stock rose 71% last year, but has since fallen back a bit. At present, Tilray stock isn’t in a buy zone or even a buy range.

Tilray has a relatively low risk profile, as long as the company is able to obtain regulatory approvals and timely renewals. The company’s revenue could increase by 340% during the next few years, but its profitability depends on the timing and level of legalization in Canada. Tilray has about 6.2 million outstanding warrants. These warrants expire in 2025.

Tilray has a strong competitive position in the global cannabis market. Its recent pivot to non-cannabis revenue streams will likely increase its staying power. Analysts expect global cannabis sales to top $248 billion by the end of this decade. The company has a global footprint of 21 countries, as well as multiple jumping-off points for federally-permissible U.S. sales. Its pipeline is strong, and it is building out its diverse revenue streams.

You may also like

Leave a Comment